CWEB vs. HLS, RX, CRDL, TGOD, NINE, MDP, DB, WMD, HEXO, and VIR
Should you be buying Charlotte's Web stock or one of its competitors? The main competitors of Charlotte's Web include HLS Therapeutics (HLS), BioSyent (RX), Cardiol Therapeutics (CRDL), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), Medexus Pharmaceuticals (MDP), Decibel Cannabis (DB), WeedMD (WMD), HEXO (HEXO), and Viridium Pacific Group (VIR). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Charlotte's Web vs. Its Competitors
HLS Therapeutics (TSE:HLS) and Charlotte's Web (TSE:CWEB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.
HLS Therapeutics has a net margin of -38.70% compared to Charlotte's Web's net margin of -66.35%. HLS Therapeutics' return on equity of -25.27% beat Charlotte's Web's return on equity.
HLS Therapeutics has higher revenue and earnings than Charlotte's Web. HLS Therapeutics is trading at a lower price-to-earnings ratio than Charlotte's Web, indicating that it is currently the more affordable of the two stocks.
0.4% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Charlotte's Web shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Charlotte's Web shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, HLS Therapeutics had 1 more articles in the media than Charlotte's Web. MarketBeat recorded 1 mentions for HLS Therapeutics and 0 mentions for Charlotte's Web. HLS Therapeutics' average media sentiment score of 0.00 equaled Charlotte's Web'saverage media sentiment score.
HLS Therapeutics currently has a consensus price target of C$5.00, indicating a potential downside of 11.50%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe HLS Therapeutics is more favorable than Charlotte's Web.
HLS Therapeutics has a beta of 0.48525, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Charlotte's Web has a beta of 2.629697, meaning that its stock price is 163% more volatile than the S&P 500.
Summary
HLS Therapeutics beats Charlotte's Web on 9 of the 14 factors compared between the two stocks.
Get Charlotte's Web News Delivered to You Automatically
Sign up to receive the latest news and ratings for CWEB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CWEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Charlotte's Web Competitors List
Related Companies and Tools
This page (TSE:CWEB) was last updated on 10/6/2025 by MarketBeat.com Staff
